Oritavancin(LY-333328) (LY 333328) 是一种具有口服活性的糖肽抗生素,对革兰氏阳性菌具有活性。
此产品仅用于科学研究,我们不为任何个人用途提供产品和服务
Oritavancin is a novel semisynthetic glycopeptide antibiotics. On August 6, 2014, the FDA approved oritavancin for treatment of skin infections. Oritavancin possesses potent and rapid bactericidal activity in vitro against a broad spectrum of both resistant and susceptible Gram-positive bacteria, including Staphylococcus aureus, MRSA, enterococci, and streptococci.